Oncolytics Biotech (ONCY) Institutional Ownership $0.98 -0.03 (-2.97%) (As of 11/15/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Oncolytics Biotech (NASDAQ:ONCY)CurrentInstitutional OwnershipPercentage6.82%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$295.63KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$20.96K Get ONCY Insider Trade Alerts Want to know when executives and insiders are buying or selling Oncolytics Biotech stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ONCY Institutional Buying and Selling by Quarter Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Oncolytics Biotech Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails10/22/2024 International Assets Investment Management LLC174,331$152K0.0%-12.1%0.228% 5/20/2024Virtu Financial LLC51,889$55K0.0%N/A0.068% 1/24/2024 International Assets Investment Management LLC269,699$364K0.0%+33.9%0.362% 1/12/2024 Advisor Resource Council100,000$135K0.0%N/A0.134% 1/11/2024 Ausdal Financial Partners Inc.30,000$40K0.0%+50.0%0.041% 11/8/2023 Ausdal Financial Partners Inc.20,000$44K0.0%N/A0.027% Get the Latest News and Ratings for ONCY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. 10/13/2023 Brave Asset Management Inc.25,000$55K0.0%+150.0%0.035% 10/10/2023 International Assets Investment Management LLC201,453$449K0.0%+3.3%0.278% 10/4/2023 International Assets Investment Management LLC201,453$449K0.0%+3.3%0.278% 8/23/2023Headinvest LLC11,534$30K0.0%N/A0.016% 8/2/2023 Bank of Montreal Can32,380$85K0.0%N/A0.049% 7/24/2023 Brave Asset Management Inc.10,000$26K0.0%N/A0.015% 7/20/2023 International Assets Investment Management LLC194,963$507K0.1%+3.4%0.297% 2/7/2023Lynwood Capital Management Inc.25,000$41K0.0%N/A0.041% 1/24/2023 International Assets Investment Management LLC169,111$609K0.1%-6.9%0.276% 1/20/2023 Newman Dignan & Sheerar Inc.18,915$31K0.0%+46.5%0.031% 8/11/2022 Toronto Dominion Bank35,362$34K0.0%N/A0.061% 7/27/2022 Advisor Resource Council100,000$101K0.0%N/A0.173% 2/14/2022 Long Focus Capital Management LLC40,000$56K0.0%N/A0.073% 2/11/2022 Advisor Resource Council100,000$139K0.0%N/A0.182% 11/12/2021 Renaissance Technologies LLC209,900$439K0.0%+812.6%0.382% 10/28/2021 International Assets Investment Management LLC170,576$357K0.1%+5.4%0.310% 10/7/2021 Newman Dignan & Sheerar Inc.12,915$27K0.0%N/A0.023% 9/17/2021Virtu Financial LLC35,425$98K0.0%N/A0.064% 8/19/2021 Advisor Resource Council101,000$280K0.0%N/A0.184% 8/13/2021 Renaissance Technologies LLC23,000$64K0.0%N/A0.042% 8/12/2021 JPMorgan Chase & Co.150,673$919K0.0%+167.7%0.274% 8/12/2021 Bank of Montreal Can16,460$46K0.0%+40.1%0.030% 7/31/2021 Brave Asset Management Inc.20,000$55K0.0%+100.0%0.036% 5/21/2021 Citadel Advisors LLC49,378$188K0.0%N/A0.093% 5/19/2021 Chiron Capital Management LLC10,000$38K0.0%N/A0.019% 5/19/2021 Squarepoint Ops LLC11,650$44K0.0%N/A0.022% 5/18/2021 Citadel Advisors LLC49,378$188K0.0%N/A0.093% 5/17/2021 Royal Bank of Canada27,381$105K0.0%-23.0%0.052% 5/17/2021 Goldman Sachs Group Inc.10,300$39K0.0%N/A0.019% 5/12/2021 Geode Capital Management LLC24,545$92K0.0%+51.4%0.046% 5/12/2021 JPMorgan Chase & Co.56,283$214K0.0%N/A0.107% 5/11/2021 Toronto Dominion Bank22,465$85K0.0%+190.5%0.043% 5/11/2021 Banque Cantonale Vaudoise11,268$42K0.0%+723.7%0.021% 4/26/2021 Brave Asset Management Inc.10,000$38K0.0%N/A0.019% Strange: Why is Amazon suddenly yielding 39.70%? (Ad)Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else →4/19/2021 International Assets Investment Management LLC277,852$885K0.1%+130.1%0.533% 2/24/2021Virtu Financial LLC19,587$47K0.0%N/A0.047% 2/10/2021 Renaissance Technologies LLC174,220$415K0.0%+1,284.3%0.418% 1/29/2021 Creative Planning180,000$428K0.0%+5.9%0.390% 1/22/2021 International Assets Investment Management LLC120,776$287K0.1%+29.3%0.290% 11/12/2020 JPMorgan Chase & Co.16,483$101K0.0%+212.0%0.040% (Data available from 1/1/2016 forward) ONCY Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ONCY shares? During the previous two years, 9 institutional investors and hedge funds held shares of Oncolytics Biotech. The most heavily invested institutionals were International Assets Investment Management LLC ($152K), Advisor Resource Council ($135K), Bank of Montreal Can ($85K), Virtu Financial LLC ($55K), Brave Asset Management Inc. ($55K), Lynwood Capital Management Inc. ($41K), and Ausdal Financial Partners Inc. ($40K).Learn more on ONCY's institutional investors. What percentage of Oncolytics Biotech stock is owned by institutional investors? 6.82% of Oncolytics Biotech stock is owned by institutional investors. Learn more on ONCY's institutional investor holdings. Which institutional investors have been buying Oncolytics Biotech stock? Of the 9 institutional investors that purchased Oncolytics Biotech stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Advisor Resource Council ($100K), International Assets Investment Management LLC ($87.57K), Virtu Financial LLC ($51.89K), Bank of Montreal Can ($32.38K), Ausdal Financial Partners Inc. ($30K), Brave Asset Management Inc. ($25K), and Lynwood Capital Management Inc. ($25K). How much institutional buying is happening at Oncolytics Biotech? Institutional investors have bought a total of 369,369 shares in the last 24 months. This purchase volume represents approximately $607.42K in transactions. Which Oncolytics Biotech major shareholders have been selling company stock? The following institutional investors have sold Oncolytics Biotech stock in the last 24 months: International Assets Investment Management LLC ($36.53K). How much institutional selling is happening at Oncolytics Biotech? Institutional investors have sold a total of 36,534 shares in the last 24 months. This volume of shares sold represents approximately $41.28K in transactions. Related Companies Enlivex Therapeutics Institutional Ownership YS Biopharma Institutional Ownership Alpha Teknova Institutional Ownership iTeos Therapeutics Institutional Ownership Sutro Biopharma Institutional Ownership SNDL Institutional Ownership uniQure Institutional Ownership Rezolute Institutional Ownership ProQR Therapeutics Institutional Ownership Zura Bio Institutional Ownership This page (NASDAQ:ONCY) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
